

**15 December 2023**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**for**

**Ropinirol "Actavis", prolonged-release tablets**

**0. D.SP.NO.**

25051

**1. NAME OF THE MEDICINAL PRODUCT**

Ropinirol "Actavis"

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each prolonged-release tablet contains 2 mg ropinirole (as hydrochloride).

Each prolonged-release tablet contains 3 mg ropinirole (as hydrochloride).

Each prolonged-release tablet contains 4 mg ropinirole (as hydrochloride).

Each prolonged-release tablet contains 6 mg ropinirole (as hydrochloride).

Each prolonged-release tablet contains 8 mg ropinirole (as hydrochloride).

Excipients with known effect

Each 2 mg prolonged-release tablet contains 64.97 mg lactose monohydrate

Each 3 mg prolonged-release tablet contains 61.83 mg lactose monohydrate

Each 4 mg prolonged-release tablet contains 59.12 mg lactose monohydrate.

Each 6 mg prolonged-release tablet contains 60.66 mg lactose monohydrate.

Each 8 mg prolonged-release tablet contains 55,88 mg lactose monohydrate.

Each Ropinirol "Actavis" prolonged-release tablet contains approximately 0.2 mg glucose (component of maltodextrin) and 50 mg hydrogenated castor oil.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Prolonged-release tablets

Ropinirol "Actavis" 2 mg prolonged-release tablets

Pink, mottled, oval tablet, 16.0×8.20 mm, with 2× debossed on one side.

Ropinirol "Actavis" 3 mg prolonged-release tablets

Purple, mottled, oval tablet, 16.0×8.20 mm, with 3× debossed on one side.

Ropinirol "Actavis" 4 mg prolonged-release tablets

Brown, mottled, oval tablet, 16.0×8.20 mm, with 4× debossed on one side.

Ropinirol "Actavis" 6 mg prolonged-release tablets

White, oval tablet, 16.0×8.20 mm, with 6× debossed on one side.

Ropinirol "Actavis" 8 mg prolonged-release tablets

Dark pink, mottled, oval tablet, 16.0×8.20 mm, with 8× debossed on one side.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Treatment of Parkinson’s disease under the following conditions:

- Initial treatment as monotherapy, in order to delay the introduction of levodopa.

- In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on‑off” type fluctuations).

**4.2 Posology and method of administration**

**Posology**

Adults

Individual dose titration against efficacy and tolerability is recommended. Ropinirol "Actavis" prolonged-release tablets should be taken once a day, at a similar time each day. The prolonged-release tablets may be taken with or without food (see section 5.2).

*Initial titration*

The starting dose of ropinirole prolonged-release tablets is 2 mg once daily for the first week; this should be increased to 4 mg once daily from the second week of treatment. A therapeutic response may be seen at a dose of 4 mg once daily of ropinirole prolonged-release tablets.

Patients who initiate treatment with a dose of 2 mg/day of ropinirole prolonged-release tablets and who experience undesirable effects that they cannot tolerate, may benefit from switching to treatment with ropinirole film-coated (immediate release) tablets at a lower daily dose, divided into three equal doses.

*Therapeutic regimen*

Patients should be maintained on the lowest dose of ropinirole prolonged-release tablets that achieve symptomatic control.

If sufficient symptomatic control is not achieved or maintained at a dose of 4 mg once daily of ropinirole prolonged-release tablets, the daily dose may be increased by 2 mg at weekly or longer intervals up to a dose of 8 mg once daily of ropinirole prolonged-release tablets.

If sufficient symptomatic control is still not achieved or maintained at a dose of 8 mg once daily of ropinirole prolonged-release tablets, the daily dose may be increased by 2 mg to 4 mg at two weekly or longer intervals. The maximum daily dose of ropinirole prolonged-release tablets is 24 mg.

It is recommended that patients are prescribed the minimum number of ropinirole prolonged-release tablets that are necessary to achieve the required dose by utilising the highest available strengths of ropinirole prolonged-release tablets.

If treatment is interrupted for one day or more, re-initiation by dose titration should be considered (see above).

When Ropinirol "Actavis" prolonged-release tablets are administered as adjunct therapy to levodopa, it may be possible to reduce gradually the levodopa dose, depending on the clinical response. In clinical trials, the levodopa dose was reduced gradually by approximately 30 % in patients receiving ropinirole prolonged-release tablets concurrently.

In patients with advanced Parkinson’s disease receiving ropinirole prolonged-release tablets in combination with L‑dopa, dyskinesias can occur during the initial titration of ropinirole prolonged-release tablets. In clinical trials it was shown that a reduction of the L‑dopa dose may ameliorate dyskinesia (see section 4.8).

When switching treatment from another dopamine agonist to ropinirole, the marketing authorisation holder’s guidance on discontinuation should be followed before initiating ropinirole.

*Treatment discontinuation*

As with other dopamine agonists, it is necessary to discontinue ropinirole treatment gradually by reducing the daily dose over the period of one week (see section 4.4).

*Switching from ropinirole film-coated (immediate-release) tablets to Ropinirol "Actavis" prolonged-release tablets* Patients may be switched overnight from ropinirole film-coated (immediate-release) tablets to Ropinirol "Actavis"prolonged-release tablets. The dose of Ropinirol "Actavis" prolonged-release tablets should be based on thetotal daily dose of ropinirole film-coated (immediate-release) tablets that the patient was taking. The tablebelow shows the recommended dose of Ropinirol "Actavis" prolonged-release tablets for patients switchingfrom ropinirole film-coated (immediate-release) tablets:

*Switching from ropinirole film-coated (immediate-release) tablets to Ropinirol "Actavis" prolonged-release tablets*

|  |  |
| --- | --- |
| Ropinirole film-coated  (immediate-release) tablets  Total daily dose (mg) | Ropinirol "Actavis" prolonged-release tablets  Total daily dose (mg) |
| 0.75 – 2.25 | 2 |
| 3 – 4.5 | 4 |
| 6 | 6 |
| 7.5 – 9 | 8 |
| 12 | 12 |
| 15 – 18 | 16 |
| 21 | 20 |
| 24 | 24 |

After switching to Ropinirol "Actavis" prolonged-release tablets, the dose may be adjusted depending on the therapeutic response (see “Initial titration” and “Therapeutic regimen” above).

*Paediatric population*

Ropinirol "Actavis" prolonged-release tablets are not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy.

*Elderly*

The clearance of ropinirole is decreased by approximately 15 % in patients aged 65 years or above. Although a dose adjustment is not required, ropinirole dose should be individually titrated, with careful monitoring of tolerability, to the optimal clinical response. In patients aged 75 years and above, slower titration during treatment initiation may be considered.

*Renal impairment*

In patients with mild to moderate renal impairment (creatinine clearance between 30 and 50 ml/min) no change in the clearance of ropinirole was observed, indicating that no dosage adjustment is necessary in this population.

The use of ropinirole in patients with severe renal impairment (creatinine clearance less than 30 ml/min) without regular haemodialysis has not been studied.

A study into the use of ropinirole in patients with end stage renal disease (patients on haemodialysis) has shown that a dose adjustment in these patients is required as follows: the recommended initial dose of ropinirole is 2 mg once daily. Further dose escalations should be based on tolerability and efficacy. The recommended maximum dose of ropinirole is 18 mg/day in patients receiving regular haemodialysis. Supplemental doses after haemodialysis are not required (see section 5.2).

**Method of administration**

Oral use.

Ropinirol "Actavis" prolonged-release tablets must be swallowed whole and must not be chewed, crushed or divided.

**4.3 Contraindications**

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Severe renal impairment (creatinine clearance <30 ml/min) without regular haemodialysis.

- Hepatic impairment.

**4.4 Special warnings and precautions for use**

Somnolence and episodes of sudden sleep onset

Ropinirole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson’s disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported (see section 4.8). Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with ropinirole. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. A reduction of dosage or termination of therapy may be considered.

Psychiatric or psychotic disorders

Patients with major psychiatric or psychotic disorders, or a history of these disorders, should not be treated with dopamine agonists unless the potential benefits outweigh the risks.

Impulse control disorders

Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including Ropinirol "Actavis" (see section 4.8). Dose reduction/tapered discontinuation should be considered if such symptoms develop.

Mania

Patients should be regularly monitored for the development of mania. Patients and carers should be made aware that symptoms of mania can occur with or without the symptoms of impulse control disorders in patients treated with ropinirole. Dose reduction/tapered discontinuation should be considered if such symptoms develop.

Neuroleptic malignant syndrome

Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore, it is recommended to taper treatment (see section 4.2).

Rapid gastrointestinal transit

Ropinirol "Actavis" tablets are designed to release medication over a 24 hour period. If rapid gastrointestinal transit occurs, there may be risk of incomplete release of medication, and of medication residue being passed in the stool.

Hypotension

Due to the risk of hypotension, blood pressure monitoring is recommended, particularly at the start of treatment, in patients with severe cardiovascular disease (in particular coronary insufficiency).

Dopamine agonist withdrawal syndrome (DAWS)

DAWS has been reported with dopamine agonists, including ropinirole (see section 4.8). To discontinue treatment in patients with Parkinson’s disease, ropinirole should be tapered off (see section 4.2). Limited data suggests that patients with impulse control disorders and those receiving high daily dose and/or high cumulative doses of dopamine agonists may be at higher risk for developing DAWS. Withdrawal symptoms may include apathy, anxiety, depression, fatigue, sweating and pain and do not respond to levodopa. Prior to tapering off and discontinuing ropinirole, patients should be informed about potential withdrawal symptoms. Patients should be closely monitored during tapering and discontinuation. In case of severe and/or persistent withdrawal symptoms, temporary re-administration of ropinirole at the lowest effective dose may be considered.

Hallucinations

Hallucinations are known as a side effect of treatment with dopamine agonists and levodopa. Patients should be informed that hallucinations can occur.

Excipients

*Lactose*

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

*Glucose (component of maltodextrin)*

This medicinal product contains glucose. Patients with rare glucose-galactose malabsorption should not take this medicine.

*Castor oil*

This medicinal product contains castor oil. This may cause stomach upset and diarrhoea.

*Sodium*

This medicinal product contains less than 1 mmol sodium (23 mg) per prolonged-release tablet, that is to say essentially “sodium-free”.

**4.5 Interaction with other medicinal products and other forms of interaction**

Levodopa and domperidone

There is no pharmacokinetic interaction between ropinirole and levodopa or domperidone which would necessitate dosage adjustment of these medicinal products.

Neuroleptics and other centrally active dopamine antagonists

Neuroleptics and other centrally active dopamine antagonists, such as sulpiride or metoclopramide, may diminish the effectiveness of ropinirole and therefore, concomitant use of these medicinal products should be avoided.

Oestrogens

Increased plasma concentrations of ropinirole have been observed in patients treated with high doses of oestrogens. In patients already receiving hormone replacement therapy (HRT), ropinirole treatment may be initiated in the normal manner. However, it may be necessary to adjust the ropinirole dose, in accordance with clinical response, if HRT is stopped or introduced during treatment with ropinirole.

CYP1A2-inhibitors

Ropinirole is principally metabolised by the cytochrome P450 isoenzyme CYP1A2. A pharmacokinetic study (with a ropinirole film-coated (immediate-release) tablet dose of 2 mg, three times a day) in Parkinson’s disease patients, revealed that ciprofloxacin increased the Cmax and AUC of ropinirole by 60 % and 84 % respectively, with a potential risk of adverse events. Hence, in patients already receiving ropinirole, the dose of ropinirole may need to be adjusted when medicinal products known to inhibit CYP1A2, e.g. ciprofloxacin, enoxacin or fluvoxamine, are introduced or withdrawn.

A pharmacokinetic interaction study in patients with Parkinson’s disease between ropinirole (with a ropinirole film-coated (immediate-release) tablet dose of 2 mg, three times a day) and theophylline, a substrate of CYP1A2, revealed no change in the pharmacokinetics of either ropinirole or theophylline.

Vitamin K antagonists

In patients receiving the combination of vitamin K antagonists and ropinirole, cases of unbalanced INR have been reported. Increased clinical and biological surveillance (INR) is warranted.

Smoking

Smoking is known to induce CYP1A2 metabolism, therefore if patients stop or start smoking during treatment with ropinirole, dose adjustment may be required.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

There are no adequate data from the use of ropinirole in pregnant women. Ropinirole concentrations may gradually increase during pregnancy (see section 5.2).

Studies in animals have shown reproductive toxicity (see section 5.3). As the potential risk for humans is unknown, it is recommended that ropinirole is not used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the foetus.

Breast-feeding

Ropinirole-related material was shown to transfer into the milk of lactating rats. It is unknown whether ropinirole and its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Ropinirole should not be used in nursing mothers as it may inhibit lactation.

Fertility

There are no data on the effects of ropinirole on human fertility. In female fertility studies in rats, effects were seen on implantation but no effects were seen on male fertility (see section 5.3).

**4.7 Effects on ability to drive and use machines**

Traffic warning.

Patients being treated with ropinirole and presenting with hallucinations, somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see section 4.4).

**4.8 Undesirable effects**

Undesirable effects reported are listed below by system organ class and frequency. It is noted if these undesirable effects were reported in clinical trials as monotherapy or adjunct therapy to levodopa.

Frequencies are defined as: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (frequency cannot be estimated from the available data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

The following adverse drug reactions have been reported in either Parkinson’s disease clinical trials with ropinirole prolonged‑release or film-coated (immediate-release) tablets at doses up to 24 mg/day, or from post-marketing reports:

|  |  |  |  |
| --- | --- | --- | --- |
|  | **In monotherapy** | **In adjunct therapy** | |
| *Immune system disorders* | | | |
| Not known | Hypersensitivity reactions (including urticaria, angiooedema, rash, pruritus) | | |
| *Psychiatric disorders* | | | |
| Common | Hallucinations | | |
|  | Confusion | |
| Uncommon | Psychotic reactions (other than hallucinations) including delirium, delusion, paranoia. | | |
| Not known | Impulse control disorders: pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Ropinirol "Actavis" (see section 4.4). | | |
| Mania (see section 4.4), aggression1, dopamine dysregulation syndrome | | |
| *Nervous system disorders* | | | |
| Very common | Somnolence, syncope | Somnolence2, dyskinesia3 | |
| Common | Dizziness (including vertigo), sudden onset of sleep | | |
| Uncommon | Excessive daytime somnolence | | |
| *Vascular disorders* | | | |
| Common |  | Postural hypotension, hypotension | |
| Uncommon | Postural hypotension, hypotension |  | |
| *Respiratory, thoracic and mediastinal disorders* | | | |
| Uncommon | Hiccups |  | |
| *Gastrointestinal disorders* | | | |
| Very common | Nausea | Nausea4 | |
| Common | Constipation, heartburn | | |
| Vomiting, abdominal pain | |  |
| *Hepatobiliary disorders* | | | |
| Not known | Hepatic reactions, mainly increased liver enzymes | | |
| *Reproductive system and breast disorders* | | | |
| Not known | Spontaneous penile erection | | |
| *General disorders and administration site conditions* | | | |
| Common | Oedema peripheral | | |
| Leg oedema |  | |
| Not known | Dopamine agonist withdrawal syndrome (including apathy, anxiety, depression, fatigue, sweating and pain)5 | | |

\* Aggression has been associated with psychotic reactions as well as compulsive symptoms.

2 Somnolence has been reported very commonly in the adjunct therapy immediate-release clinical trials, and commonly in the adjunct therapy prolonged-release clinical trials.

3 In patients with advanced Parkinson’s disease, dyskinesias can occur during the initial titration of ropinirole. In clinical trials it was shown that a reduction of the levodopa dose may amelioratedyskinesia (see section 4.2).

4 Nausea has been reported very commonly in the adjunct therapy immediate-release clinical trials, and commonly in the adjunct therapy prolonged-release clinical trials.

5 Non-motor adverse effects may occur when tapering or discontinuing dopamine agonists including ropinirole (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Lægemiddelstyrelsen

Axel Heides Gade 1

DK-2300 København S

Websted: www.meldenbivirkning.dk

**4.9 Overdose**

The symptoms of ropinirole overdose are related to its dopaminergic activity. These symptoms may be alleviated by appropriate treatment with dopamine antagonists such as neuroleptics or metoclopramide.

**4.10 Legal status**

B

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Dopaminergic agents, dopamine agonist, ATC-code: N04BC04.

Mechanism of action

Ropinirole is a non ergoline D2/D3 dopamine agonist which stimulates striatal dopamine receptors.

Ropinirole alleviates the dopamine deficiency which characterises Parkinson’s disease by stimulating striatal dopamine receptors.

Ropinirole acts in the hypothalamus and pituitary to inhibit the secretion of prolactin.

Clinical efficacy

A 36‑week, double‑blind, three-period crossover study, in monotherapy, conducted in 161 patients with early phase Parkinson’s disease demonstrated that ropinirole prolonged-release tablets were noninferior to ropinirole film-coated (immediate-release) tablets on the primary endpoint, the treatment difference in change from baseline in the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score (a 3‑point non‑inferiority margin on the UPDRS motor score was defined). The adjusted mean difference between ropinirole prolonged-release tablets and ropinirole film-coated (immediate-release) tablets at study endpoint was -0.7 points (95 % CI: [-1.51, 0.10], p = 0.0842).

Following the overnight switch to a similar dose of the alternative tablet formulation, there was no difference in the adverse event profile and less than 3 % of patients required a dose adjustment (all dose adjustments were increases by one dose level. No patients required a dose decrease).

A 24‑week, double‑blind, placebo-controlled, parallel group study of ropinirole prolonged-release tablets in patients with Parkinson’s disease who were not optimally controlled on levodopa demonstrated a clinically relevant and statistically significant superiority over placebo on the primary endpoint, change from baseline in awake time “off” (adjusted mean treatment difference -1.7 hours (95 % CI: [-2.34, -1.09], p< 0.0001). This was supported by secondary efficacy parameters of change from baseline in total awake time “on” (+1.7 hours (95 % CI: [1.06, 2.33], p< 0.0001) and total awake time “on” without troublesome dyskinesias (+1.5 hours (95 % CI: [0.85, 2.13], p< 0.0001). Importantly, there was no indication of an increase from baseline in awake time “on” with troublesome dyskinesias, either from diary card data or from the UPDRS items.

Study of the effect of ropinirole on cardiac repolarisation

A thorough QT study conducted in male and female healthy volunteers who received doses of 0.5, 1, 2 and 4 mg of ropinirole film-coated (immediate release) tablets once daily showed a maximum increase of the QT interval duration at the 1 mg dose of 3.46 milliseconds (point estimate) as compared to placebo. The upper bound of the one sided 95 % confidence interval for the largest mean effect was less than 7.5 milliseconds. The effect of ropinirole at higher doses has not been systematically evaluated.

The available clinical data from a thorough QT study do not indicate a risk of QT prolongation at doses of ropinirole up to 4 mg/day. A risk of QT prolongation cannot be excluded as a thorough QT study at doses up to 24 mg/day has not been conducted.

**5.2 Pharmacokinetic properties**

Absorption

Bioavailability of ropinirole is approximately 50 % (36‑57 %). Following oral administration of ropinirole prolonged-release tablets plasma concentrations increase slowly, with a median time to Cmax generally achieved between 6 and 10 hours.

In a steady-state study in 25 Parkinson’s disease patients receiving 12 mg of ropinirole prolonged release tablets once daily, a high fat meal increased the systemic exposure to ropinirole as shown by an average 20 % increase in AUC and an average 44 % increase in Cmax. Tmax was delayed by 3.0 hours. However, these changes are unlikely to be clinically relevant (e.g. increased incidence of adverse events).

The systemic exposure to ropinirole is comparable for ropinirole prolonged-release tablets and ropinirole film-coated (immediate-release) tablets based on the same daily dose.

Distribution

Plasma protein binding of ropinirole is low (10–40 %). Consistent with its high lipophilicity, ropinirole exhibits a large volume of distribution (approx. 7 l/kg).

Biotransformation

Ropinirole is primarily cleared by CYP1A2 metabolism and its metabolites are mainly excreted in the urine. The major metabolite is at least 100‑times less potent than ropinirole in animal models of dopaminergic function.

Elimination

Ropinirole is cleared from the systemic circulation with an average elimination half‑life of about 6 hours. The increase in systemic exposure (Cmax and AUC) to ropinirole is approximately proportional over the therapeutic dose range. No change in the oral clearance of ropinirole is observed following single and repeated oral administration. Wide inter-individual variability in the pharmacokinetic parameters has been observed. Following steady-state administration of ropinirole prolonged-release tablets, the inter-individual variability for Cmax was between 30 % and 55 % and for AUC was between 40 % and 70 %.

Renal impairment

There was no change observed in the pharmacokinetics of ropinirole in Parkinson’s disease patients with mild to moderate renal impairment.

In patients with end stage renal disease receiving regular haemodialysis, oral clearance of ropinirole is reduced by approximately 30 %. Oral clearance of the metabolites SKF‑104557 and SKF‑89124 were also reduced by approximately 80 % and 60 %, respectively. Therefore, the recommended maximum dose is limited to 18 mg/day in these patients with Parkinson’s disease (see section 4.2).

Pregnancy

Physiological changes in pregnancy (including decreased CYP1A2 activity) are predicted to gradually lead to an increased maternal systemic exposure of ropinirole (see section 4.6).

**5.3 Preclinical safety data**

Reproductive toxicity

In fertility studies in female rats, effects were seen on implantation due to the prolactin-lowering effect of ropinirole. It should be noted that prolactin is not essential for implantation in humans.

Administration of ropinirole to pregnant rats at maternally toxic doses resulted in decreased foetal body weight at 60 mg/kg/day (mean AUC in rats approximately twice the highest AUC at the Maximum Recommended Human Dose (MRHD)), increased foetal death at 90 mg/kg/day (approximately 3 times the highest AUC at the MRHD) and digit malformations at 150 mg/kg/day (approximately 5 times the highest AUC at the MRHD). There were no teratogenic effects in the rat at 120 mg/kg/day (approximately 4 times the highest AUC at the MRHD) and no indication of an effect during organogenesis in the rabbit when given alone at 20 mg/kg (9.5 times the mean human Cmax at the MRHD). However, ropinirole at 10 mg/kg (4.8 times the mean human Cmax at the MRHD) administered to rabbits in combination with oral L-dopa produced a higher incidence and severity of digit malformations than L-dopa alone.

Toxicology

The toxicology profile is principally determined by the pharmacological activity of ropinirole: behavioural changes, hypoprolactinaemia, decrease in blood pressure and heart rate, ptosis and salivation. In the albino rat only, retinal degeneration was observed in a long term study at the highest dose (50 mg/kg/day), and was probably associated with an increased exposure to light.

Genotoxicity

Genotoxicity was not observed in the usual battery of *in vitro* and *in vivo* tests.

Carcinogenicity

From two‑year studies conducted in the mouse and rat at dosages up to 50 mg/kg/day there was no evidence of any carcinogenic effect in the mouse. In the rat, the only ropinirole-related lesions were Leydig cell hyperplasia and testicular adenoma resulting from the hypoprolactinaemic effect of ropinirole. These lesions are considered to be a species specific phenomenon and do not constitute a hazard with regard to the clinical use of ropinirole.

Safety pharmacology

*In vitro* studies have shown that ropinirole inhibits hERG-mediated currents. The IC50 is 5‑fold higher than the expected maximum plasma concentration in patients treated at the highest recommended dose (24 mg/day), see section 5.1.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Hypromellose

Croscarmellose sodium

Maltodextrin (contains glucose)

Lactose monohydrate

Hydrogenated castor oil

Colloidal anhydrous silica

Magnesium stearate

Pigment Blend (not applicable for 6 mg prolonged-release tablets)

*2 mg prolonged-release tablets*

Iron oxide red (E172)

Iron oxide yellow (E172)

Lactose monohydrate

*3 mg prolonged-release tablets*

Lactose monohydrate

Indigo Carmine Aluminium Lake (E132)

Carmine (E120)

*4 mg and 8 mg prolonged-release tablets*

Iron oxide red (E172)

Iron oxide yellow (E172)

Lactose monohydrate

Iron oxide black (E172)

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years.

**6.4 Special precautions for storage**

Do not store above 30 °C.

**6.5 Nature and contents of container**

Blister (aluminium/aluminium)

Pack sizes: 21, 28, 30, 42, 56, 84 and 90 prolonged-release tablets.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Actavis Group PTC ehf.

Reykjavikurvegur 76-78

220 Hafnarfjordur

Island

**8. MARKETING AUTHORISATION NUMBER(S)**

2 mg: 47979

3 mg: 47980

4 mg: 47981

6 mg: 47982

8 mg: 47983

**9. DATE OF FIRST AUTHORISATION**

17 September 2008 (film-coated tablets)

**10. DATE OF REVISION OF THE TEXT**

15 December 2023